- Home
- SPRB vs PIRS Comparison
SPRB vs PIRS Comparison
Compare SPRB & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRB
- PIRS
- Stock Information
- Founded
- SPRB 2014
- PIRS 2001
- Country
- SPRB United States
- PIRS United States
- Employees
- SPRB N/A
- PIRS N/A
- Industry
- SPRB Medicinal Chemicals and Botanical Products
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- SPRB Health Care
- PIRS Health Care
- Exchange
- SPRB Nasdaq
- PIRS Nasdaq
- Market Cap
- SPRB 22.8M
- PIRS 22.4M
- IPO Year
- SPRB 2020
- PIRS N/A
- Fundamental
- Price
- SPRB $0.52
- PIRS $16.10
- Analyst Decision
- SPRB Hold
- PIRS
- Analyst Count
- SPRB 7
- PIRS 0
- Target Price
- SPRB $2.50
- PIRS N/A
- AVG Volume (30 Days)
- SPRB 400.8K
- PIRS 35.0K
- Earning Date
- SPRB 11-11-2024
- PIRS 11-13-2024
- Dividend Yield
- SPRB N/A
- PIRS N/A
- EPS Growth
- SPRB N/A
- PIRS N/A
- EPS
- SPRB N/A
- PIRS N/A
- Revenue
- SPRB $7,101,000.00
- PIRS $20,872,000.00
- Revenue This Year
- SPRB N/A
- PIRS N/A
- Revenue Next Year
- SPRB N/A
- PIRS N/A
- P/E Ratio
- SPRB N/A
- PIRS N/A
- Revenue Growth
- SPRB N/A
- PIRS N/A
- 52 Week Low
- SPRB $0.41
- PIRS $6.20
- 52 Week High
- SPRB $5.95
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- SPRB 47.26
- PIRS 41.31
- Support Level
- SPRB $0.51
- PIRS $15.69
- Resistance Level
- SPRB $0.56
- PIRS $16.88
- Average True Range (ATR)
- SPRB 0.03
- PIRS 0.52
- MACD
- SPRB -0.01
- PIRS -0.12
- Stochastic Oscillator
- SPRB 16.61
- PIRS 20.40
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.